MedTrace Logo

Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine

NCT02146469 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2014-05-23

No results posted yet for this study

Summary

The objective of the study is as follows:

1. To know the antibody level during different interval after received 1 dose varicella vaccine.
2. To know safety and effectiveness of received 2 doses varicella vaccine with different interval.
3. To know safety and effectiveness of received varicella vaccine and MMR at the same time.

To achieve that, this study selects children with specific varicella vaccine history, gives 1 or 2 doses varicella vaccine, collects blood specimens and makes a follow-up visit after vaccination.

All blood specimens will be tested by a third-party detection institution.

Conditions

  • Varicella

Interventions

BIOLOGICAL

2 doses with an 3 months interval

varicella vaccination

BIOLOGICAL

A second dose with an 1 year interval

varicella vaccine

BIOLOGICAL

A second dose with an 3 year interval

varicella vaccine

BIOLOGICAL

A second dose with an 5 year interval

varicella vaccine

BIOLOGICAL

1 dose Varicella vaccine and 1 dose MMR given at the same time

varicella vaccine and MMR

BIOLOGICAL

1 dose MMR

MMR

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    collaborator INDUSTRY

  • Shanghai Municipal Center for Disease Control and Prevention

    lead OTHER

Principal Investigators

  • Xiaodong Sun · Shanghai Municipal Center for Disease Control and Prevention

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-06-30
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146469 on ClinicalTrials.gov